Peptide safety checker: how to read a peptide Certificate of Analysis

Why peptide safety matters

The gap between a pharmaceutical-grade manufacturer and an unregulated vendor is rarely visible on a website. What separates them is documentation: a Certificate of Analysis reporting identity, purity, and contamination testing for the exact batch on offer. The checker below turns that into 8 questions and a grade.

The peptide sourcing landscape ranges from pharmaceutical-grade manufacturers to unregulated vendors with no quality controls, and the difference between them is not always obvious from a website or a product label. What matters is the documentation behind the product, specifically the Certificate of Analysis (COA). If you are still deciding whether peptides make sense for your situation, the beginner's guide to whether peptides are right for you is a useful first read.

A COA is a report from a testing laboratory that describes the identity, purity, and contamination status of a specific batch of peptide. It typically includes HPLC purity analysis, mass spectrometry confirmation, and endotoxin testing. Without this document, there is no objective way to know what you have.

That gap is not theoretical. A review of impurities in peptide medicines catalogues what routinely appears alongside the intended molecule when peptides are made by solid-phase synthesis: deletion and insertion sequences from inefficient coupling or deprotection, racemized residues and the diastereomers they create, oxidized side chains, protection adducts, dimers and larger oligomers, and residual trifluoroacetate counter ions [1]. The same review notes that these impurities can distort conclusions in early research, not only in finished products, which is precisely the position a buyer holding no COA is in.

This tool walks you through 8 quality indicators, one at a time. Based on your answers you receive a grade from A to F with a breakdown showing where a supplier meets or falls short of each benchmark. Read the grade as a description of paperwork, not as a verdict on the vial in your hand.

Anatomy of a Certificate of Analysis

A COA has a predictable structure: lab identification, sample and batch identification, HPLC purity, mass spectrometry identity, endotoxin results, sterility results, and batch dates. Each block answers a different question, and a missing block is information in itself. The interactive document below explains all seven.

Click any section of the sample Certificate of Analysis below to see what that block should contain and what should make you slow down. The layout is representative rather than universal: laboratories format their reports differently, but the same seven kinds of information should be findable somewhere on a complete document.

Reading the blocks in order is the fastest way to catch a problem. The header tells you who did the testing and whether they are independent of the seller. The sample block tells you which batch was tested. The analytical blocks tell you what the testing found. If any one of those three layers is missing, the ones that remain cannot compensate: an impressive purity figure attached to no batch number describes a peptide you cannot prove you received.

Red flags to watch for

Some warning signs are worth more than others. No COA at all, no batch number, and no independent testing are structural failures, because they remove the ability to check anything else. Missing mass spectrometry, missing endotoxin data, and suspiciously round purity figures are next. Any single flag warrants caution.

These warning signs point to possible quality or safety problems with a supplier. Any single red flag warrants caution, and several together suggest the supplier should simply be avoided.

• No COA available: the most basic quality document. If a supplier cannot provide one, move on.
• COA from an in-house lab only: the supplier is testing their own product with no independent verification.
• Missing mass spectrometry data: without MS, identity is unconfirmed. You know something is pure, but not what it is.
• Purity below 95%: the remaining share can include truncated sequences, deletion peptides, and chemical byproducts of synthesis.
• No batch or lot numbers: without traceability there is no way to connect the COA to the product you received.
• Claims that seem too good: "100% pure guaranteed" or "pharmaceutical grade" with no document behind it.
• Pricing far below market average: quality synthesis is expensive, and extremely low prices often reflect cut corners.
• No endotoxin testing: for anything intended for injection, this is a critical safety test.
• COA dates that do not match the product batch: reusing an old COA for a new batch is a common shortcut.
• No verifiable online presence: established suppliers have reviews, community reputation, and transparent business information.

Endotoxin deserves its own note, because it is the flag most often waved away. Pyrogens, the fever-inducing contaminants that include bacterial endotoxin, are not destroyed by standard sterilisation, and once in the bloodstream they can produce reactions ranging from fever to septic shock [2]. The LAL test that appears on a COA detects endotoxin specifically, which is useful but narrow: a passing LAL result does not rule out non-endotoxin pyrogens, which is why sterility testing is reported separately rather than folded into the same line.

How to verify a COA without being a chemist

Start with traceability: peptide name, batch number, test date, and supplier label should all describe the same lot. Then check that the document contains real test outputs rather than assertions. A purity percentage with no chromatogram is a claim, and an identity claim with no mass spectrometry is incomplete.

Start with traceability. The peptide name, batch number, test date, and supplier label should all point to the same lot. If the product page shows one lot number and the COA shows another, the document is closer to generic marketing material than to proof about the vial in front of you.

Next, check whether the document contains actual test outputs. A purity percentage without an HPLC chromatogram is just a claim. An identity claim without mass spectrometry is incomplete. For anything meant to be sterile or injectable, endotoxin and sterility data should be present rather than implied by a phrase like "lab tested."

It also helps to know that a purity number is a property of a method, not only of a peptide. A study comparing five chromatographic systems on cationic peptides found that the column, the acidic modifier, and the column temperature all changed the apparent result, and that a poorly chosen system can produce misleading purity values for basic peptides; the same work showed that adding a mass spectrometry detector lets a lab identify both the peptide and its impurities and assess whether a peak is actually pure [3]. This is why "98% by HPLC" with no stated method is weaker evidence than the number suggests, and why MS is not an optional extra.

Pharmacopoeial chapters exist for exactly this reason. USP General Chapter 621 and Ph. Eur. 2.2.29 define how chromatography should be performed and reported, and USP General Chapter 85 covers the bacterial endotoxins test. A COA that names the method it followed is telling you something a COA that reports a bare number is not. Endotoxin acceptance limits, incidentally, are derived from the maximum dose per kilogram of body weight rather than being one fixed figure per milligram of peptide, so a limit quoted with no reference to dose is not meaningful on its own.

Why independent testing changes the risk profile

Independent testing does not make a product medical grade, but it removes one conflict of interest. A third-party laboratory has less incentive to inflate purity, omit a failed run, or reuse a passing document across later batches. Batch-specific testing from a lab you can identify and contact is the strongest arrangement available to a buyer.

Independent testing does not make a product medical grade, but it removes one conflict of interest. A third-party lab has less incentive to inflate purity, omit failed runs, or reuse a passing document across future batches. The strongest setup is batch-specific testing from a laboratory that can be identified and contacted.

There is a further reason independence matters: a purity or content figure only means something relative to a well-characterised reference standard. Work describing how peptide reference standards are established shows the value assigned to a standard comes from integrating results across multiple laboratories, using a two-step process that first assigns a value to bulk material and then to the vialed material, with identity confirmed separately by methods such as NMR and mass spectrometry [4]. A single unverified in-house number carries none of that structure behind it.

The industry framing for this is that quality is built into a process rather than tested into a finished batch at the end, the core idea behind quality by design in biopharmaceutical manufacturing [5]. A buyer cannot audit a supplier's process, so documentation is the only proxy available. The checker weights missing documentation heavily because peptide quality failures are frequently invisible: a vial can look completely normal while containing truncated sequences, residual solvents, an incorrect concentration, or bacterial byproducts. Documentation is imperfect, but without it there is no way to separate quality control from branding. For a broader walkthrough of vetting a source from scratch, see the guide on reading COAs, HPLC reports, and third-party testing results.

What the grade is trying to prevent

The goal is not to crown a perfect supplier. It is to screen out avoidable unknowns before they become your problem. A high grade means a supplier is at least showing the documents that let you ask better questions. A low grade means too many basic controls are missing or cannot be verified at all.

The goal is not to crown a perfect supplier. It is to screen out avoidable unknowns before they become your problem. A high grade means the supplier is at least showing the documents that let you ask better questions. A low grade means too many basic controls are missing or unverifiable.

Treat "research use only" as a risk label, not a loophole. Many peptides discussed online are not approved medicines for the claims attached to them, and supplier quality varies widely. The peptide craze explained breaks down which claims are grounded in evidence and which are marketing. If a product is being considered in a medical context, the right path is a licensed clinician and a regulated pharmacy, not a gray-market workaround.

Common document tricks

Watch for cropped screenshots, a COA with no laboratory address, absent analyst signatures, identical chromatograms across different products, and purity values rounded suspiciously neatly across many batches. None of these proves fraud on its own, but each is a reason to slow down and ask for batch-specific documentation.

Watch for cropped screenshots, COAs with no lab address, missing analyst signatures, identical chromatograms across different products, and purity values rounded too neatly across many batches. None of those details proves fraud by itself, but each one justifies slowing down and asking for batch-specific documentation.

When a supplier answers those questions clearly, keep the records. Saving batch numbers, invoices, and COAs makes future comparison easier and helps you notice when documentation quality changes over time. That history is part of your safety file. Understanding the difference between natural and synthetic peptides is also worth reviewing when evaluating what a supplier is actually selling, and the peptide storage and stability calculator covers what happens to a well-documented peptide after it arrives.